Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|February 1, 2008
Many schizophrenic patients stop taking drugs due to side effects
Survey finds a low drug compliance rate among schizophrenic patients
Advertisement
A survey of 250 patients with
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.
The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
Adults with serious mental illness receive GLP-1 prescriptions at rates similar to or higher than their peers, though schizophrenia continued to lag.
Advertisement
Advertisement
Trending on Drug Topics
1
Nicotine Pouches Create Opportunity for Pharmacist Counseling
2
Worth a Shot: How ACIP Changes Might Impact Vaccine Access, Coverage
3
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
4
FDA Approves Finerenone for Chronic Kidney Disease With Type 1 Diabetes
5